6 05, 2021

Novel Drug Offers Rapid Relief From Agitation in Serious Mental Illness

By |2021-05-06T09:36:50-07:00May 6th, 2021|Brief Bulletins from the Field, Featured, We Know Psychiatry|0 Comments

An investigational, orally dissolving film formulation of dexmedetomidine (BXCL501, BioXcel Therapeutics) may offer rapid relief from acute agitation related to schizophrenia or bipolar disorder (BD), results of two phase 3, randomized, placebo-controlled trials show. Dr Leslie Citrome For both disorders, BXCL501 showed "superiority over placebo" by meeting the primary endpoint of reduction of agitation as [...]

19 01, 2021

Associations between breast cancer survivorship and adverse mental health outcomes: A matched population-based cohort study in the United Kingdom

By |2021-01-19T12:45:20-08:00January 19th, 2021|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

SUMMARY In this study, we observed that compared to women with no prior cancer, breast cancer survivors had higher risk of anxiety, depression, sleep problems, sexual dysfunction, fatigue, receipt of opioid analgesics, and pain. Relative risks estimates tended to decrease over time, but anxiety and depression were significantly increased for [...]

20 10, 2020

Suicide Prevention in the COVID-19 Era Transforming Threat Into Opportunity

By |2020-10-20T09:07:02-07:00October 20th, 2020|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

From: JAMA Psychiatry. Published online October 16, 2020. doi:10.1001/jamapsychiatry.2020.3746 By Christine Moutier, MD Introduction International and US experts on suicide have expressed concerns about the potential the coronavirus disease 2019 (COVID-19) pandemic has to increase the risk of suicide through its effects on a number of well-established suicide risk factors.1,2 Suicide surveillance [...]

6 08, 2020

CBD Can Improve Mental and Physical Health

By |2020-10-02T11:42:02-07:00August 6th, 2020|Brief Bulletins from the Field, Featured|5 Comments

With a vast range of medical and therapeutic benefits, CBD, or cannabidiol, is a derivative of the hemp plant. Researches have supported the claims that CBD may be a potential natural alternative to several traditional medicines. Consequently, CBD has become an ever-increasing industry. From pain-relieving balms to skin serums and [...]

29 07, 2020

A Comprehensive Update of Lofexidine for the Management of Opioid Withdrawal Symptoms

By |2020-07-29T09:04:39-07:00July 29th, 2020|Brief Bulletins from the Field|0 Comments

The current maintenance treatment for opiate withdrawal usually includes using a different, controlled, opiate, either methadone or buprenorphine. Alpha-2 receptor agonists, such as lofexidine, can be used to manage the acute symptoms during withdrawal. Lofexidine is effective and safe and is FDA approved for the management of withdrawal symptoms. It [...]

29 07, 2020

Naldemedine for the Use of Management of Opioid Induced Constipation

By |2020-07-29T08:59:49-07:00July 29th, 2020|Brief Bulletins from the Field|0 Comments

According to Urits and Viswanath, Opioid medications are fundamental in anesthesia and analgesia and are often used to treat acute and chronic pain. They achieve their desired effects by modulating pain perception in the central nervous system; however, they also act on opioid receptors in the periphery, causing many undesirable [...]

4 06, 2020

Antiepileptic Drugs and Bone Health: Current Concepts

By |2020-06-04T10:53:56-07:00June 4th, 2020|Brief Bulletins from the Field, We Know Psychiatry|3 Comments

Chronic use of antiepileptic drugs (AEDs) can induce the development of adverse effects on bone metabolism. In epileptic patients treated with AED, the monitor- ing of biochemical markers of bone turnover, such as the measurement of serum 25 (OH) vitamin D, bone mineral density, before the beginning of the treatment [...]

4 06, 2020

Demographic Variation in the Use of Prazosin for Treatment of Sleep Disturbance in Combat Veterans with PTSD

By |2020-06-04T10:47:07-07:00June 4th, 2020|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

ABSTRACT ~ Objective: Off-label use of prazosin for posttraumatic stress disorder-related sleep disturbances (PTSD-SD) is widespread in Veterans Health Administration (VA) settings, but clinical trials have had mixed results. Trial criteria may exclude significant sub-groups, and therefore a 2018 study may not provide the final evidence of prazo- sin efficacy [...]

Go to Top